Search tips
Search criteria 


Logo of bmjThe BMJ
BMJ. 1993 August 28; 307(6903): 537–540.
PMCID: PMC1678609

Obesity as a determinant for response to antihypertensive treatment.


OBJECTIVE--To test the hypothesis that beta blockers lower blood pressure more effectively than calcium entry blockers in obese hypertensive patients and that calcium entry blockers are more effective in lean patients. DESIGN--Double blind, randomised controlled trial of treatment over six weeks. SETTING--Tertiary referral centre. SUBJECTS--42 white men with uncomplicated mild to moderate essential hypertension (World Health Organisation stage I or II); 36 completed the study. INTERVENTION--Patients were randomised to metoprolol 50-100 mg twice daily or isradipine 2.5-5.0 mg twice daily for six weeks after a two week run in phase. MAIN OUTCOME MEASURE--Blood pressure after six weeks of treatment. RESULTS--When stratified according to treatment and presence of obesity (body mass index < or = 27 kg/m2), the mean (SD) fall in blood pressure in the beta blocker group was 24 (13)/18 (10) mm Hg in obese patients and 18 (19)/12 (13) mm Hg in lean patients. In the calcium entry blocker group, the fall in blood pressure was 21 (15)/17 (6) mm Hg in lean patients and 18 (11)/8 (10) mm Hg in obese patients. After taking age and blood pressure before treatment into account there was a significant interaction between obesity and drug therapy (p = 0.019) with a better diastolic blood pressure response to calcium entry blockers in lean patients and to beta blockers in obese hypertensive patients. CONCLUSION--Obesity affects the efficacy of metoprolol and isradipine in reducing blood pressure.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827–838. [PubMed]
  • Bühler FR. Antihypertensive treatment according to age, plasma renin and race. Drugs. 1988 May;35(5):495–503. [PubMed]
  • Kaplan NM. Calcium entry blockers in the treatment of hypertension. Current status and future prospects. JAMA. 1989 Aug 11;262(6):817–823. [PubMed]
  • Messerli FH. Cardiopathy of obesity--a not-so-Victorian disease. N Engl J Med. 1986 Feb 6;314(6):378–380. [PubMed]
  • Messerli FH, Sundgaard-Riise K, Reisin E, Dreslinski G, Dunn FG, Frohlich E. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med. 1983 May;74(5):808–812. [PubMed]
  • Messerli FH, Sundgaard-Riise K, Reisin ED, Dreslinski GR, Ventura HO, Oigman W, Frohlich ED, Dunn FG. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med. 1983 Dec;99(6):757–761. [PubMed]
  • Julius S. Are different hemodynamic patterns of antihypertensive drugs clinically important? Eur J Clin Pharmacol. 1990;38 (Suppl 2):S125–S128. [PubMed]
  • Kusaka M, Atarashi K, Matsumoto K, Sumida Y, Matsuura H, Shingu T, Kajiyama G. Plasma renin activity and norepinephrine as predictors for antihypertensive effects of nifedipine and captopril. Am J Hypertens. 1991 Sep;4(9):735–739. [PubMed]
  • Nicholson JP, Resnick LM, Laragh JH. The antihypertensive effect of verapamil at extremes of dietary sodium intake. Ann Intern Med. 1987 Sep;107(3):329–334. [PubMed]
  • Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension. 1988 Sep;12(3):244–250. [PubMed]
  • Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982 Apr;62(2):347–504. [PubMed]
  • Tuck ML, Sowers JR, Dornfeld L, Whitfield L, Maxwell M. Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol (Copenh) 1983 Feb;102(2):252–257. [PubMed]
  • Sowers JR, Whitfield LA, Catania RA, Stern N, Tuck ML, Dornfeld L, Maxwell M. Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab. 1982 Jun;54(6):1181–1186. [PubMed]

Articles from The BMJ are provided here courtesy of BMJ Publishing Group